Thursday , March 4 2021

Owners of Karo Pharmas should ask for answers from Lönner



Anders Lönner, the chairman and principal owner of Karo Pharma, was previously accused of having put his own interests in front of other shareholders.

For example, he guaranteed new problems and borrowed money for the company at non-market prices.

His salvation has always been a brilliant businessman who attracts new shareholders. Anders Lönner built the Meda pharmaceutical company with great success, which was later sold to the US company Mylan for SEK 62 billion.

Now he and the council recommend other owners to please EOQ's offer for Karo Pharma. It's weird, because it would be like selling Meda when the company began to develop and stabilize its economy. Because there is Karo Pharma in a situation where the risk has fallen and the potential has begun to materialize. In addition, the business is not cyclically sensitive.

In recent years, the company has shifted its emphasis from preclinical capital research to specialized niche medications and product development close to marketing. Karo Pharma, for example, is behind top sellers as the "dosetten" capsule dispenser, and strong brands as a prescription pain reliever Citodon.

Why Lönner, like other investors, has reasonably seen the chance of making a new Meda de Karo Pharma, selling the company at low prices? He's a good businessman to do it. So, what are you supposed to guide?

Part of the answer might be that he is prosecuted for suspected breach of gross insider. In February, the trial will begin and if Anders Lönner is tried, he may have a ban on nutrition. Then Karo Pharma stands out without the highest leader, and the course is likely to collapse. But at the same time, this means that the other council misunderstood their duty when they let him go instead of getting the replacement of the president.

For Lönner personally, a free speech means that EQT can leave it to the Karo Pharma Council outside of the stock market. He can then participate in the continuous growth journey with limited risk.

Other owners, especially institutions such as Catella and Swedbank, should ask members to explain why they think SEK 6 billion is well paid for a growing company that is beginning to flourish.

This is a text from today's industry leadership edition. The industry today is independent.


Source link